المؤلفون: D'Yakov I.N., Zyryanov S.K.

المصدر: Onkourologiya

مصطلحات موضوعية: Advanced renal cell carcinoma, Aksitinib, Bevacizumab, Everolimus, Interferon alfa, Pazopanib, Renal carcinoma, Sunitinib, Target therapy, Tyrosine kinase inhibitor

العلاقة: https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test; https://openrepository.ru/article?id=254814Test

الإتاحة: https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test
https://openrepository.ru/article?id=254814Test

المؤلفون: B. Alekseev Ya., A. Kalpinskiy S., K. Nyushko M., I. Taraki A., A. Kaprin D., Б. Алексеев Я., А. Калпинский С., К. Нюшко М., И. Тараки А., А. Каприн Д.

المصدر: Cancer Urology; Том 12, № 3 (2016); 22-29 ; Онкоурология; Том 12, № 3 (2016); 22-29 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-3

مصطلحات موضوعية: metastatic renal cell carcinoma, targeted therapy, tyrosine kinase inhibitors, sunitinib, aksitinib, метастатический почечно-клеточный рак, таргетная терапия, ингибиторы тирозинкиназ, сунитиниб, акситиниб

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/604/573Test; https://oncourology.abvpress.ru/oncur/article/view/604/640Test; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.frTest/ Pages/fact_sheets_population.aspx.; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Malignant tumors in Russia in 2014 (morbidity and fatality). Ed. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2016. (In Russ.)].; Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601–9.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 2007;356:115–24.; Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.; Hudes G., Carduc C.I. M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56. DOI:10.1016/S0140- 6736(08)61039-9.; Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103–11.; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. 2016. Available at: http://www.nccn.orgTest/.; Ljungberg B., Bensalah K., Bex A. et al. Volpe Guidelines on renal cell cancer. European Association of Urology 2016. Available at: http://www.uroweb.orgTest/.; Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009;20(Suppl 19): i7–12. DOI:10.1093/ annonc/mdp073.; Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295: 2516–24.; Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90. DOI:10.1200/JCO.2008.20.1293.; Motzer R.J., Hutson T.E., Olsen M.R. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:1371–7. DOI:10.1200/ JCO.2011.36.4133.; Neri B., Vannini A., Brugia M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients. Int J Urol 2013;20(5):478–83. DOI:10.1111/j.1442-2042.2012.03204.x.; Kondo T., Takagi T., Kobayashi H. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma – comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol 2014;44:270–7. DOI:10.1093/jjco/hyt232.; Najjar Y.G., Mittal K., Elson P. et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014;50:1084–99. DOI:10.1016/j.ejca.2014.01.025.; Atkinson B.J., Kalra S., Wang X. et al. Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules. J Urol 2014;191(3):611–8. DOI:10.1016/ j.juro.2013.08.090.; Bracarda S., Iacovelli R. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2015;26:2107–13. DOI:10.1093/annonc/mdv315.; Houk B.E., Bello C.L., Poland B. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357–71. DOI:10.1007/s00280-009-1170-y.; Abel E.J., Culp S.H., Tannir N.M. et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 2011;60:1273–9. DOI:10.1016/j.eururo.2011.07.008.; Molina A.M., Lin X., Korytowsky B. et al. Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. Eur J Cancer 2014;50:351–8. DOI:10.1016/j.ejca.2013.08.021.; Knox J.J., Barrios C.H., Kim T.M. et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). J Clin Oncol 2015;33(suppl; abstr 4554). DOI:10.1200/JCO.2013.54.6911.; DavisI.D., Long A., Yip S. et al. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Ann Oncol 2015;26(6):1118–23. DOI:10.1093/annonc/mdv078.; Motzer R.J., Escudier B., Tomczak P. et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trial. Lancet Oncol 2013;14:552–62. DOI:10.1016/S1470-2045(13)70093-7; Rini B.I., Quinn D.I., Baum M. et al. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 2015;10(1):45–53. DOI:10.1007/s11523-014-0307-z.; Escudier B., Michaelson M.D., Motzer R.J. et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomized phase III trial. Br J Cancer 2014;110(12):2821–8. DOI:10.1038/bjc.2014.244.; Rini B.I., Garrett M., Poland B. et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 2013;53(5):491–504. DOI:10.1002/jcph.73.; Rini B.I., Melichar B., Fishman M.N. et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015;26(7): 1372–7. DOI:10.1093/annonc/mdv103.; https://oncourology.abvpress.ru/oncur/article/view/604Test

الإتاحة: https://doi.org/10.17650/1726-9776-2016-12-3-22-29Test
https://doi.org/10.17650/1726-9776-2016-12-3Test
https://doi.org/10.1016/S0140Test
https://doi.org/10.1200/JCO.2008.20.1293Test
https://doi.org/10.1111/j.1442-2042.2012.03204.xTest
https://doi.org/10.1093/jjco/hyt232Test
https://doi.org/10.1016/j.ejca.2014.01.025Test
https://doi.org/10.1093/annonc/mdv315Test
https://doi.org/10.1007/s00280-009-1170-yTest
https://doi.org/10.1016/j.eururo.2011.07.008Test

المؤلفون: I. D’yakov N., S. Zyryanov K., И. Дьяков Н., С. Зырянов К.

المصدر: Cancer Urology; Том 12, № 4 (2016); 43-51 ; Онкоурология; Том 12, № 4 (2016); 43-51 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4

مصطلحات موضوعية: renal carcinoma, advanced renal cell carcinoma, target therapy, tyrosine kinase inhibitor, pazopanib, sunitinib, aksitinib, bevacizumab, interferon alfa, everolimus, рак почки, распространенный почечноклеточный рак, таргетная терапия, ингибитор тирозинкиназ, пазопаниб, сунитиниб, акситиниб, бевацизумаб, интерферон альфа, эверолимус

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/640/598Test; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 2016. 250 с. [Malignant tumors in Russia in 2014 (morbidity and fatality). Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: FGBU “Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institut im. P.A. Gertsena” – filial FGBU “Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr” Minzdrava Rossii, 2016. 250 p. (In Russ.)].; Алексеев Б.Я., Калпинский А.С. Эффективность применения таргетной терапии в гетерогенной популяции больных метастатическим раком почки. Онкоурология 2012; (3):37–42. [Alekseev B.Ya., Kalpinskiy A.S. Efficiency of targeted therapy used in the heterogeneous population of patients with metastatic kidney cancer. Onkourologiya = Oncourology 2012;(3):37–42. (In Russ.)].; Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108. PMID: 15761078.; Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология 2013;(1):28–33. [Matveev V.B., Volkova M.I. Sequential targeted therapy for disseminated kidney cancer. Onkourologiya =Oncourology 2013;(1):28–33. (In Russ.)].; Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163(2): 408–17. PMID: 10647643.; Fojo A.T., Shen D.W., Mickley L.A. et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5(12):1922–7. PMID: 3681376.; Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85(8):1130–6. PMID: 11710825. PMCID: PMC2375150. DOI:10.1054/bjoc.2001.2076.; Huland E., Heinzer H. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alphainterferon (leucocyte) and tamoxifen. Br J Cancer 2000;82(1):246–7. PMID: 10638997. PMCID: PMC2363186. DOI:10.1054/bjoc.1999.0952.; Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14–7. PMID: 10023944.; Oliver R.T., Miller R.M., Mehta A., Barnett M.J. A phase II study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998;1(1):14–20. PMID: 3267368.; Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148(4):1247–8. PMID: 1404646.; Atkins M.B., Regan M., McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18):6342S–6S. PMID: 15448028. DOI:10.1158/1078-0432.CCR-040029.; Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6 (Suppl 1):55–7. PMID: 10685660.; McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133–41. PMID: 15625368. DOI:10.1200/JCO.2005.03.206.; Motzer R.J., Murphy B.A., Bacik J. et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(16):2972–80. PMID: 10944130.; Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338(18):1272–8. PMID: 9562581. DOI:10.1056/NEJM199804303381805.; Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21(16):3127–32. PMID: 12915604. PMCID: PMC2275327. DOI:10.1200/JCO.2003.02.122.; SEER. Program coding and staging manual 2007 Appendix C Part 6: C64.9–C80.9. 2008. Available at: http://seer.cancer.gov/tools/codingmanualsTest/.; Wahlgren T., Harmenberg U., Sandstrom P. et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer 2013;108(7):1541–9. PMID: 23531701. PMCID: PMC3629428. DOI:10.1038/bjc.2013.119.; Gnarra J.R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85–90. PMID: 7915601. DOI:10.1038/ng0594-85.; Iliopoulos O., Levy A.P., Jiang C. et al. Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc Natl Acad Sci USA 1996;93(20):10595–9. PMID: 8855223. PMCID: PMC38198.; Maxwell P.H., Wiesener M.S., Chang G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399(6733):271–5. PMID: 10353251. DOI:10.1038/20459.; Na X., Wu G., Ryan C.K. et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxiainducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003;170:588–92.; de Paulsen N., Brychzy A., Foumier M.C. et al. Role of transforming growth factor-alpha in von Hippel–Lindau (VHL)(–/–) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl AcadSci USA 2001;98(4):1387–92. PMID: 11171960. PMCID: PMC29266. DOI:10.1073/pnas.031587498.; Hutson T.E., Lesovoy V., Al-Shukri S. et al. Axitinib versus sorafenib as firstline therapy in patients with metastatic renal-cell carcinoma: a randomisedopenlabel phase III trial. Lancet Oncol 2013;14(13):1287–94. PMID: 24206640. DOI:10.1016/S1470-2045(13)70465-0.; Motzer R.J., Barrios C.H., Kim T.M. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(25):2765–72. PMID: 25049330. DOI:10.1200/JCO.2013.54.6911.; Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722—31. PMID: 23964934. DOI:10.1056/NEJMoa1303989.; Motzer R.J., Nosov D., Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a Phase III trial. J Clin Oncol 2013;31(30):3791–9. PMID: 24019545. DOI:10.1200/JCO.2012.47.4940.; Rini B.I., Bellmunt J., Clancy J. et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752–9. DOI:10.1200/JCO.2013.50.5305.; Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505–12. PMID: 16636341. DOI:10.1200/JCO.2005.03.6723.; Escudier B., Bellmunt J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144–50. PMID: 20368553. DOI:10.1200/JCO.2009.26.7849.; Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. PMID: 20368558. PMCID: PMC2860433. DOI:10.1200/JCO.2009.26.5561.; Hurwitz H., Dowlati A., Savage S. et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005;23:195.; Hutson T., Davis I., Machiels J. et al: Predictive and prognostic factors in phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Ann Oncol 2008;19:187.; Abrams T.J., Lee L.B., Murray L.J. et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471–8. PMID: 12748309.; Mendel D.B., Laird A.D., Xin X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamics relationship. Clin Cancer Res 2003;9:327–37.; Rini B.I., Rixe O., Bukowski R.M. et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase II study of cytokinerefractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005;23:4509.; Sonpavde G., Hutson T.E., Rini B.I. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17(5):741–8. PMID: 18447599. DOI:10.1517/13543784.17.5.741.; Flaherty K.T. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007;13(2): 747s–52s. PMID: 17255304. DOI:10.1158/1078-0432.CCR-06-2063.; O’Farrell A.M., Abrams T.J., Yuen H.A. et al. SU11248 is a novel FLT-3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597–605. PMID: 12531805. DOI:10.1182/blood-2002-07-2307.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24. PMID: 17215529. DOI:10.1056/NEJMoa065044.; Chang X., Zhang F., Liu T. et al. Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget 2016;7(13):15801–10. PMID: 26908455. PMCID: PMC4941278. DOI:10.18632/oncotarget.7511.; Larkin J., Paine A., Foley G. et al. Firstline treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother 2015;16(13):1915–27. PMID: 26194211. DOI:10.1517/14656566.2015.1058359.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of randomized Phase III trial. J Clin Oncol 2010;28(6):1061–8. PMID: 20100962. DOI:10.1200/JCO.2009.23.9764.; Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422–8. РMID: 18936475. PMCID: PMC2651074. DOI:10.1200/JCO.2008.16.9847.; Bergmann L., Kube U., Doehn C. et al. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer 2015;15:303. PMID: 25925846. PMCID: PMC4413536. DOI:10.1186/s12885-015-1309-7.; Buchler T., Bortlicek Z., Poprach A. et al. Efficacy of everolimus in second- and thirdline therapy for metastatic renal cell carcinoma: a registry-based analysis. Urol Oncol 2014;32(5):569–75. PMID: 24629497. DOI:10.1016/j.urolonc.2013.12.007.; Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18): 4256–65. PMID: 20549832. DOI:10.1002/cncr.25219.; Thiery-Vuillemin A., Theodore C., Jacobasch L. et al. Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab with or without interferon therapy: results from the european AVATOR study. Clin Genitourin Cancer 2015;13(3):231–8. PMID: 25456838. DOI:10.1016/j.clgc.2014.09.005.; Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial. Lancet 2011;378(9807):1931–9. PMID: 22056247. DOI:10.1016/S0140-6736(11)61613-9.; Vogelzang N.J., Pal S.K., Signorovitch J.E. et al. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Curr Med Res Opin 2016;32(4):741–7. PMID: 26744781. DOI:10.1185/03007995.2016.1140028.; Remak E., Charbonneau C., Negrier S. et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(24): 3996–4000. PMID: 18711190. DOI:10.1200/JCO.2007.13.2662.; Benedict A., Figlin R.A., Sandström P. et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 2011;108(5): 665–72. PMID: 21265994. DOI:10.1111/j.1464-410X.2010.09957.x.; Ravasio R., Ortega C., Sabbatini R., Porta C. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig 2011;31(7): 507–17. PMID: 21627339. DOI:10.2165/11590230-000000000-00000.; Delea T.E., Amdahl J., Diaz J. et al. Costeffectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm 2015;21(1):46–54, 54a–b. PMID: 25562772. DOI:10.18553/jmcp.2015.21.1.46.; Kilonzo M., Hislop J., Elders A. et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics 2013;31(1):15–24. PMID: 23329590. DOI:10.1007/s40273-012-0006-5.; MacLean E.A., Sandin R., Mardekian J. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015;21(9):841–3. PMID: 26308231. DOI:10.18553/jmcp.2015.21.9.841.; Villa G., Hernández-Pastor L.J. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer 2013;13:399. PMID: 24004638. PMCID: PMC3856525. DOI:10.1186/1471-2407-13-399.; Hansen R.N., Hackshaw M.D., Nagar S.P. et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm 2015;21(1):37–44. PMID: 25562771. DOI:10.18553/jmcp.2015.21.1.37. Зырянов С.К., Фролов М.Ю., Дьяков И.Н. Клинико-экономическая оценка применения пазопаниба в терапии распространенного рака почки. Онкоурология 2016;12(1): 106–18. [Zyryanov S.K., Frolov M.Yu., D’yakov I.N. Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer. Onkourologiya = Cancerurology 2016;12(1):106–18. (In Russ.)]. DOI: 10.17 650/1726-9776-2016-12-1-106-114.; Perrin A., Sherman S., Pal S. et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ 2015;18(3):200–9. PMID: 25422989. DOI:10.3111/13696998.2014.985789.; Casciano R., Chulikavit M., Di Lorenzo G. et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health 2011;14(6):846–51. PMID: 21914504. DOI:10.1016/j.jval.2011.04.008.; Petrou P. Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert Opin Pharmacother 2015;16(8):1233–43. PMID: 25958963. DOI:10.1517/14656566.2015.1039982.; https://oncourology.abvpress.ru/oncur/article/view/640Test

الإتاحة: https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test
https://doi.org/10.17650/1726-9776-2016-12-4Test
https://doi.org/10.1054/bjoc.2001.2076Test
https://doi.org/10.1054/bjoc.1999.0952Test
https://doi.org/10.1158/1078-0432.CCR-040029Test
https://doi.org/10.1200/JCO.2005.03.206Test
https://doi.org/10.1056/NEJM199804303381805Test
https://doi.org/10.1200/JCO.2003.02.122Test
https://doi.org/10.1038/bjc.2013.119Test
https://doi.org/10.1038/ng0594-85Test

المؤلفون: Vrdoljak, Eduard, Bošković, Lidija, Petrić Miše, Branka, Boraska Jelavić, Tihana, Viculin, Jelena, Strikić, Ante, Ban, Marijan

مصطلحات موضوعية: 17-(3-piridil)-5, 16-androstadien-3beta-acetat, aflibercept, antitumorski protokoli, ARQ 197, aksitinib, bevacizumab, krizotinib, everolimus, imatinib, ipilimumab, N-(4-bromo- 2-fluorofenil)-6-metoksi-7-((1-metilpiperidin-4-il)metoksi)kinazolin-4-amin, novotvorine, pazopanib, pertuzumab, PLX4032, ridaforolimus, sunitinib, trastuzumab

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::01171e0cf1e76c61e72b03d4015b4355Test
https://www.bib.irb.hr/1258366Test

المؤلفون: D'Yakov I.N., Zyryanov S.K.

المصدر: Onkourologiya

مصطلحات موضوعية: Advanced renal cell carcinoma, Aksitinib, Bevacizumab, Everolimus, Interferon alfa, Pazopanib, Renal carcinoma, Sunitinib, Target therapy, Tyrosine kinase inhibitor

العلاقة: https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test; https://repository.rudn.ru/records/article/record/4258Test/

الإتاحة: https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test
https://repository.rudn.ru/records/article/record/4258Test/

المصدر: Onkourologiya

مصطلحات الفهرس: Advanced renal cell carcinoma, Aksitinib, Bevacizumab, Everolimus, Interferon alfa, Pazopanib, Renal carcinoma, Sunitinib, Target therapy, Tyrosine kinase inhibitor, Article

URL: http://hdl.handle.net/rour/254814uriTest
https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test
https://doi.org/10.17650/1726-9776-2016-12-4-43-51Test